Helio Genomics Partners with Syneos Health to Drive Awareness & Adoption of HelioLiver

Helio Genomics, an AI-powered TechBio company focused on revolutionizing early cancer detection, has partnered with Syneos Health, a fully integrated biopharmaceutical solutions organization, to drive awareness and adoption of HelioLiver, Helio Genomics’ blood-based test for the early detection of hepatocellular carcinoma (HCC), the most common form of liver cancer.

Helio Genomics plans to harness Syneos Health’s extensive commercialization expertise, national field deployment capabilities, and proven ability to engage healthcare providers (HCPs).

“Partnering with Syneos Health represents a major leap forward in our commercialization strategy and de-risks the path to broad market adoption of HelioLiver,” said Dr. Bharat Tewarie, CEO of Helio Genomics. “Syneos Health’s decades of experience successfully building and executing commercial programs will accelerate HCP engagement across the country. Together, we will expand access to this innovative test, empowering clinicians to detect liver cancer earlier and deliver better outcomes for patients who need it most.”

“We are proud to partner with Helio Genomics to advance their breakthrough approach to detecting liver cancer at its most treatable stages,” said Paul Mignon, President & Global Head, Deployment Solutions, Syneos Health.

Syneos Health will deploy targeted field engagement, deliver tailored educational initiatives and execute integrated promotional strategies to support HelioLiver reaching hepatologists, gastroenterologists, and other providers managing high-risk populations nationwide. This will be underpinned by the predictive and adaptive analytics capabilities of Syneos Health’s AI-powered Kinetic platform, designed to connect, harmonize and streamline end-to-end commercial solutions.